Clinical Trials Logo

ACC clinical trials

View clinical trials related to ACC.

Filter by:
  • None
  • Page 1

NCT ID: NCT01898715 Completed - Clinical trials for Adrenocortical Carcinoma

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

Start date: August 13, 2013
Phase: Phase 1
Study type: Interventional

This first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced adrenocortical carcinoma whose tumor has progressed on standard therapy. Information will also be collected to determine how long ATR-101 stays in the blood, and if any effect on tumor progression is seen. Biomarkers (blood and urine tests) will determine if any effects on production of steroid hormones (cortisol, aldosterone, estrogen and testosterone) are seen.

NCT ID: NCT01678105 Completed - ACC Clinical Trials

A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

DOVE
Start date: November 2012
Phase: Phase 2
Study type: Interventional

This is a non-randomized, phase II, open label study of dovitinib in patients with progressive, recurrent and/or metastatic adenoid cystic carcinoma (ACC). The primary purpose of this study is to assess the anti-cancer effects of dovitinib in this population in order to evaluate whether dovitinib is worthy of further study in patients with progressive ACC.

NCT ID: NCT01262235 Completed - Cancer Clinical Trials

A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for whom there is no standard therapy. After the determination of the maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with refractory neuroendocrine tumors (NET) or adrenocortical carcinoma (ACC) tumors.